Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
Information source: Office of Rare Diseases (ORD)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Diabetes Insipidus, Nephrogenic
Intervention: chlorothiazide (Drug)
Phase: N/A
Status: Completed
Sponsored by: National Center for Research Resources (NCRR) Official(s) and/or principal investigator(s):
Gary L. Robertson, Study Chair, Affiliation: Northwestern University
Summary
OBJECTIVES:
I. Determine the relationship between genotype variations and clinical phenotype in patients
with congenital nephrogenic diabetes insipidus.
Clinical Details
Study design: Screening
Detailed description:
PROTOCOL OUTLINE: A detailed family history is obtained from all participants. Whenever
possible, standard growth curves of affected children are obtained.
Participants then undergo clinical studies of antidiuretic function. A standard fluid
deprivation-vasopressin challenge is performed with timed measurements of osmolality,
electrolytes, creatinine, and vasopressin. The next day, blood pressure, plasma cyclic AMP,
GMP, von Willebrand Factor, Factor VIII, and urine osmolality are measured during a water
load desamino-D-arginine vasopressin (dDAVP) infusion test.
Participants with a confirmed diagnosis of congenital diabetes insipidus are then treated
with chlorothiazide. Daily urine volume and osmolality are determined before and after
therapy. Sodium and fluid are not restricted.
For each family, the entire vasopressin V2 gene of at least 1 affected male, and where
possible at least 1 obligate carrier and 1 unaffected brother of a patient is sequenced. In
addition, a detailed Xq28 haplotype analysis is done to identify the origin of de novo
mutations. If no mutation is found and the disorder is not transmitted in an X-linked mode,
both alleles of the gene that codes for aquaporin-II are also sequenced. DNA is collected by
mail from as many kindred as possible who do not participate in the clinical studies.
Eligibility
Minimum age: 6 Months.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
PROTOCOL ENTRY CRITERIA:
- Known or suspected congenital nephrogenic diabetes insipidus
- Clinically and genetically unaffected relatives entered as controls
- -Patient Characteristics--
- Age: 6 months to 70 years
Locations and Contacts
Additional Information
Related publications: Bichet DG, Birnbaumer M, Lonergan M, Arthus MF, Rosenthal W, Goodyer P, Nivet H, Benoit S, Giampietro P, Simonetti S, et al. Nature and recurrence of AVPR2 mutations in X-linked nephrogenic diabetes insipidus. Am J Hum Genet. 1994 Aug;55(2):278-86. Sadeghi H, Robertson GL, Bichet DG, Innamorati G, Birnbaumer M. Biochemical basis of partial nephrogenic diabetes insipidus phenotypes. Mol Endocrinol. 1997 Nov;11(12):1806-13. Robertson GL, McLeod JF, Zerbe RL, et al.: Vasopressin function in heritable
forms of diabetes insipidus. In: Gross P, Richter D, Robertson GL, eds.:
Vasopressin: IV International Vasopressin Conference, May 23-27, 1993, Berlin
Germany. Paris: John Libbey Eurotext, 1993, pp 493-503. Wenkert D, Merendino JJ Jr, Shenker A, Thambi N, Robertson GL, Moses AM, Spiegel AM. Novel mutations in the V2 vasopressin receptor gene of patients with X-linked nephrogenic diabetes insipidus. Hum Mol Genet. 1994 Aug;3(8):1429-30. No abstract available.
Starting date: September 1995
Last updated: June 23, 2005
|
